Journal Article

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

Harding, Adam C., Knight, Michael L., Adele, Sandra, Jeffery, Katie, Amini, Ali, Dunachie, Susanna J., Carroll, Miles W., Stafford, Lizzie, Adland, Emily, Klenerman, Paul, James, William S., Longet, Stephanie, Dold, Christina, Rijal, Pramila, Schimanski, Lisa, Brown, Anthony, Tipton, Tom, Goulder, Philip, Tan, Tiong Kit, Conlon, Christopher P., Johnson, Síle A., Skelly, Donal T., de Oliveira, Tulio, Brown, Helen, Huang, Kuan-Ying A., Barnes, Eleanor, Frater, John, Pollard, Andrew J., Sigal, Alex, Mentzer, Alexander J., Gilbert-Jaramillo, Javier, Townsend, Alain R.

2021

Overview

The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020. We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine. Importantly, high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. Vaccination is required to generate high potency immune responses to protect against these and other emergent variants. Understanding the effect of vaccination on emerging SARS-CoV-2 variants of concern is of increasing importance. Here, James et al. report that two doses of vaccination with the Pfizer-BioNTech vaccine induce more robust immune responses to the B.1.1.7 and B.1.351 SARS-CoV-2 lineages than does natural infection.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 101/1 / 101/47 / 13/1 / 13/106 / 631/250/2499 / 631/250/590 / 631/326/421 / 631/326/596/4130 / 82/1 / Angiotensin-Converting Enzyme 2 - immunology / Animals / Antibodies / Antibodies, Monoclonal - blood / Antibodies, Neutralizing - immunology / Antibodies, Neutralizing - isolation & purification / Antibodies, Neutralizing - metabolism / Antibodies, Viral - blood / Antibodies, Viral - immunology / Carrier Proteins / Coronaviruses / COVID-19 / COVID-19 - immunology / COVID-19 - prevention & control / COVID-19 Vaccines - administration & dosage / COVID-19 Vaccines - immunology / Epitopes / Humanities and Social Sciences / Humans / Immune response / Immunity / Immunization / Infections / Lymphocytes / Lymphocytes T / multidisciplinary / Neutralization / Respiratory diseases / Robustness / SARS-CoV-2 - drug effects / SARS-CoV-2 - immunology / Science / Science (multidisciplinary) / Severe acute respiratory syndrome coronavirus 2 / T-Lymphocytes - immunology / Vaccines / Viral diseases